ABSTRACT -Background -Due to the high prevalence of co-infection by hepatitis C virus (HCV) and human immunodeficiency virus (HIV) and the severity of these infections, the understanding of the biological mechanisms involved in these processes, including viral behavior and host genetic profile, is of great importance for patient treatment and for public health policies. Some single nucleotide polymorphisms (SNPs) in the human genome, such as the SNP rs1045642 (C3435T) in the MDR1 gene, have been reported to be associated to the sustained virological response (SVR) to HCV treatment in HCV-HIV co-infected patients. Objective -The present study analyzes the MDR1 gene C3435T polymorphism in HCV-HIV co-infected patients.
INTRODUCTION
Hepatitis C is considered a major public health problem. Approximately 3% of the human population is infected with the hepatitis C virus (HCV), which represents approximately 170 million people chronically infected and at risk of developing disease complications, including cirrhosis and hepatocellular carcinoma (17) . In Southern Brazil, the prevalence of HCV in adults (aged 20 to 69 years) is 1.7% (22) . HCV infection has been commonly observed in individuals infected with the human immunodeficiency virus (HIV), mainly because both viruses share transmission routes; notably, injecting drug users constitute a high-risk group for acquiring both HCV and HIV (18, 23) . Considering that approximately 400 million people are infected with HIV worldwide, co-infection rates have been increasing significantly; in North America and Europe, about 30% of
FREQUENCY OF THE MDR1 GENE POLYMORPHISM RS1045642 (C3435T) IN HCV-HIV CO-INFECTED PATIENTS
HIV-infected patients are co-infected with HCV (23) . In Brazil, the highest HIV detection rate is reported in the South region of the country; not surprisingly, the number of HCV-HIV co-infected individuals is also high (18) (19) (20) . In our experience, a study performed in a tertiary reference center of attendance for HIV showed a prevalence of co-infection with HCV of 38.2% (26) . After the introduction of highly active antiretroviral therapy (HAART), patients with HIV have been given a higher survival rate, enabling the development of other chronic diseases, such as liver diseases. In addition, in co-infected patients, HCV can increase morbidity and mortality related to HIV (12) . The efficacy of the treatment for hepatitis C can vary among patients, and genetic characteristics play an important role in the response to the drugs used. Some single nucleotide polymorphisms (SNPs) have been associated with HCV and HIV infections, disease outcome and response to treatment (4, 7) . The multi-drug resistance gene 1 (MDR1, NT_007933; NM_000927) is well known for its role in the resistance to drugs used in the treatment of different human diseases (21) . Also called ABCB1, the MDR1 gene is located in chromosome 7q21.1 (5) and comprises a promoter region of 29 exons, with a total of 209kb (3, 6) . MDR1 codes for the P-glycoprotein (PgP) 1, a member of the superfamily of ABC transporters (ATP-binding cassette), which includes proteins that transport a wide variety of substrates (8, 9) . It has been observed that cells that exhibit a multidrug resistance phenotype also show an increase in the expression of the PgP (27) . In 2000, Hoffemeyer et al. described 15 SNPs for the MDR1 gene, including C1236T, G2677T/A and C3435T. The latter, which is located in exon 26, has been correlated with the expression levels and activity of PgP (13) . Given the high prevalence of co-infection by HCV and HIV and the numerous complications that co-infected patients present, this work aims to map the C3435T polymorphism of the MDR1 gene (rs1045642) in HCV-HIV co-infected patients and correlate its distribution with the response to treatment for hepatitis C.
METHODS
This is a cross-sectional study that evaluated patients from a reference Hospital in Southern Brazil in the management of co-infected HCV-HIV patients. Those diagnosed with HCV and HIV, who held monitoring in the outpatient clinic from January 2013 to December 2013 were included.
Interviews were conducted with 99 patients who agreed to participate in the study and signed the Informed Consent sheet. All the 99 patients answered an information form and were submitted to blood collection in 4 mL tubes containing EDTA.
To characterize the population studied, the following variables were evaluated: age, gender, ethnicity, response to treatment with pegylated interferon and ribavirin, genotype of HCV, METAVIR score (2) , risk factors for acquiring HCV-HIV, CD4 + levels, treatment regimen for HIV (HAART) and genotype profile for the SNP rs1045642 (C3435T) of the MDR1 gene.
Patients were treated with pegylated interferon-alfa and ribavirin, and those who had a negative result for HCV-RNA at week 24 after the end of treatment were considered as having sustained virological response (SVR).
All molecular analyses were carried out at the Molecular Biology Laboratory of the Federal University of Health Sciences of Porto Alegre (UFCSPA). After blood collection, the nucleated cell layer (buffy coat) was separated by centrifugation at 500 x g for 10 minutes. The buffy coat was stored in 1.5 mL tubes and kept at -80ºC until DNA extraction.
DNA extraction was based on the methodology described by Iranpur et al. (16) . DNA was analyzed in a NanoDrop (NanoDrop Technologies, Wilmington, USA), quantified and stored at -80ºC.
For molecular identification of the C3435T polymorphism of the MDR1 gene (GenBank accession number: M29445), qPCR was performed on a Step One PLUS thermocycler (Applied Biosystems, Foster City, CA), based on allele-specific assay using a pair of primers and two hydrolysis probes, which have been designed and validated by Applied Biosystms (SNP: rs1045642). The primers were used to identify the DNA sequence containing the SNP, and the probes were classified into "Normal Probe" (used to amplify the C allele) and the "Polymorphic Probe" (to amplify the T allele).
Quantitative variables were expressed as mean, standard deviation, minimum and maximum. The qualitative variables were described by absolute and relative frequencies. To verify if there was an association between the MDR1 gene polymorphism C3435T and the patient's response to treatment, analysis was performed using the chi-square test where associations with P<0.25 were later analyzed under multivariate approach, using logistic regression. To evaluate other associations for the C3435T polymorphism, chi-square test of Pearson was used. The significance level was 5.0% and the analyses were performed using SPSS program v. 21.0.
The study was approved by the local Research Ethics Committee under the Protocol Number 12-089.
RESULTS
This study analyzed 99 patients infected with HCV and HIV. The characteristics of the patients and the distribution of genotypes of the MDR1 gene C3435T polymorphism are shown in Table 1 . The genotype frequencies for the MDR1 gene polymorphism C3435T in the total sample of co-infected patients were 28 patients (28.3%) for the homozygote genotype CC, 47 patients (47.5%) for the heterozygous genotype CT, and 24 patients (24.2%) for the homozygous genotype TT. The allelic frequency for the polymorphic variant C was 52% and the frequency of the T allele was 48% of the cases studied.
The SVR was 40%, and there was no relation with the HCV genotype. To verify the association of the SNP rs1045642 with response to treatment in HCV-HIV coinfected patients, the bivariate analysis followed by multivariate and logistic regression was used ( Table 2 ). The SVR to treatment for HCV was evaluated in 45 patients, and the variables tested were the HCV genotype, ethnicity, HAART regimen, gender and CD4 cell count. The only variable associated to SVR was the CD4 cell count, as the patients with unsatisfactory SVR showed a CD4 cell count lower than 500 cells/mm 3 (OR 5.05; P=0.049).
DISCUSSION
The treatment of HCV has been revolutionized by the new direct antiviral acting drugs (DAA), however many countries still use pegylated interferon-based regimens; therefore, it is of interest to evaluate the factors associated with SVR using these regimens.
In recent years, several studies about the MDR1 gene have sought to understand the role of SNPs in this gene and the development of diseases, as well as response to drug treatment. The literature reports an association between the C3435T polymorphism of the MDR1 gene and various diseases. Rose et al. suggest a regulatory role of MDR1 gene expression in patients with hepatopathies (24) ; other studies about this SNP have shown that the C allele is associated with a better prognosis in patients with hepatitis C and in patients with hepatocellular carcinoma (1, 25) . On the other hand, in other pathological conditions such as HIV infection, the T allele appears to confer a better prognosis; HIV-infected patients homozygous for the TT genotype, when treated with HAART, have shown significant increases in CD4 cell count and better response to the treatment of hepatitis C (11, 15, 29) . The present study analyzed the MDR1 gene polymorphism C3435T in HCV-HIV coinfected patients. The results showed similarity in the prevalence of the C allele and the T allele in the population studied, with CT being the most prevalent genotype in these patients. Among the patients with HCV infection who underwent treatment with pegylated interferon-alpha and ribavirin, our findings corroborate the results found by Timucin et al., which also showed a higher frequency for the CT genotype among these patients (25) . Some studies claim that the presence of the T allele generates no response to treatment, however we did not find such an association; furthermore, the presence of this allele is also associated with development of some type of cancers such as hepatocellular carcinoma, prostate cancer, ovarian cancer and others (28) . Besides genetic polymorphisms, other variables may have a role in the response to antiviral therapy with pegylated interferon-alpha and ribavirin in patients with hepatitis C (10, 14) . In this study, multivariate analysis showed an association between CD4 cell count and response to treatment, where individuals with scores lower than 500 cells/mm 3 are five times more likely to not have a SVR after treatment with pegylated interferon and ribavirin. No association between SVR and MDR1 SNP rs1045642 genotype was observed.
One limitation of this study was the relatively low number of patients treated with pegylated interferon-alpha and ribavirin, therefore it would be interesting to evaluate the effects of this and other polymorphisms in a larger cohort of HCV-HIV co-infected patients. Additionally, studies including patients from different geographical regions would also be valuable to better understand the role of genetic factors in HCV and improve the treatment and prognosis of patients with HCV-HIV co-infection, mainly in the DAA era. 
